ocrelizumab


( Last Updated : May 10, 2018)
Generic Name:
ocrelizumab
Project Status:
Complete
Therapeutic Area:
Primary progressive multiple sclerosis
Manufacturer:
Hoffman-La Roche Limited
Call for patient/clinician input open:
Brand Name:
Ocrevus
Project Line:
Reimbursement Review
Project Number:
SR0542-000
Call for patient/clinician input closed:

Details


Submission Type:
Initial
Fee Schedule:
Schedule B
Indications:
Primary progressive multiple sclerosis
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:

Key Milestones2

Call for patient input postedSeptember 27, 2017
Patient group input closedNovember 16, 2017
Clarification:

- Patient input submission received

Patient input summary sent for review to patient input groupsNovember 22, 2017
Patient group comments on input summary closedNovember 29, 2017
Clarification:

- Patient input summary feedback received

Submission receivedOctober 26, 2017
Submission accepted for reviewNovember 09, 2017
Review initiatedNovember 10, 2017
Draft CDR review report(s) sent to applicantFebruary 05, 2018
Comments from applicant on draft CDR review report(s) receivedFebruary 14, 2018
Redaction requests from applicant on draft CDR review report(s) receivedFebruary 22, 2018
CDR review team's comments on draft CDR review report(s) sent to applicantMarch 09, 2018
Canadian Drug Expert Committee (CDEC) meetingMarch 21, 2018
CDEC recommendation & redacted CDR review report(s) sent to applicant and drug plansApril 05, 2018
Embargo period ended and validation of redacted CDR review report(s) receivedApril 19, 2018
CDEC Final Recommendation issued to applicant and drug plansApril 26, 2018
CDEC Final Recommendation postedApril 30, 2018
Final CDR review report(s) and patient input postedMay 08, 2018